Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 6/20 | 0.43 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863747 | 0.87 | SYK (0.49) | MAPK10SYKMYLK4STK17AJAK2 | |
| SCHEMBL13336017 | 0.86 | SYK (0.45) | MAPK10JUNMAPK8MAP3K5SYK | |
| SCHEMBL3503552 | 0.85 | MAPK10 (0.51) | MAPK10MAPK8SYKMYLK4STK17A | |
| SCHEMBL3503540 | 0.82 | MAPK10 (0.54) | MAPK10SYKMYLK4STK17AJAK2 | |
| SCHEMBL3503825 | 0.81 | RIPK2 (0.44) | MAPK10SYKMYLK4STK17AJAK2 | |
| SCHEMBL1870735 | 0.81 | CCNT1 (0.55) | MAPK10JAK2RIPK2 | |
| SCHEMBL3504879 | 0.77 | MAP3K5 (0.66) | MAPK10JUNMAP3K5MAP4K1 | |
| SCHEMBL1870096 | 0.73 | MAPK10 (0.58) | MAPK10JUNMAPK8MAP4K1JAK2 | |
| SCHEMBL3503353 | 0.72 | JAK2 (0.63) | MAPK10MAPK8SYKMYLK4STK17A | |
| SCHEMBL13336001 | 0.72 | SYK (0.47) | SYKSTK17AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | claimed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 338/4885JUN 504/4885MAPK8 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.